The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ADMA BIOLOGICS INC. COM 000899104 16,598 3,608,171 SH   SOLE   3,608,171 0 0
AGILE THERAPEUTICS INC. COM 00847L100 3,354 1,304,933 SH   SOLE   1,304,933 0 0
AIMMUNE THERAPEUTICS INC. COM 00900T107 71,299 2,240,000 SH   SOLE   2,240,000 0 0
CHIMERIX INC. COM 16934W106 2,459 472,943 SH   SOLE   472,943 0 0
CIDARA THERAPEUTICS INC. COM 171757107 4,085 1,021,148 SH   SOLE   1,021,148 0 0
LOXO ONCOLOGY INC. COM 548862101 396,748 3,438,920 SH   SOLE   3,438,920 0 0
PERNIX THERAPEUTICS HLDGS INC. COM NEW 71426V306 502 210,000 SH   SOLE   210,000 0 0
PERNIX THERAPEUTICS HLDGS INC. DEBT 4.250% 4/0 71426VAK4 1,155 2,500,000 PRN   SOLE   2,500,000 0 0
TRANSENTERIX INC. COM NEW 89366M201 16,812 9,889,352 SH   SOLE   9,889,352 0 0
VIEWRAY INC. COM 92672L107 48,102 7,480,887 SH   SOLE   7,480,887 0 0